Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.

After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left ...

Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

It's a blow to the SCD community, as Oxbryta (voxelotor) was the first drug to reach the market that prevented sickle ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

The decision is based on the totality of clinical data, which now indicates that the benefit of Oxbryta no longer outweighs ...